Alumis INC

Alumis Inc. announced positive long-term data from its ONWARD3 study for envudeucitinib, showing high rates of complete skin clearance in plaque psoriasis patients and maintaining a favorable safety profile.

Alumis Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of three Class II directors and the ratification of its independent auditor.

Alumis Inc. presented an updated corporate presentation on June 29, 2026, highlighting progress and future milestones for its precision-engineered TYK2 inhibitors, envudeucitinib and A-005, targeting immune-mediated diseases.

Alumis Inc. announced its first quarter 2026 financial results, reporting a net loss of $93.1 million and highlighting positive Phase 3 data for its psoriasis drug candidate, envudeucitinib.

Envudeucitinib met all primary and secondary endpoints in two Phase 3 ONWARD trials with high Week 24 skin-clearance rates and a favorable safety profile; NDA planned for H2 2026.

Alumis Inc. announced its year-end 2025 financial results, highlighted by positive Phase 3 data for envudeucitinib in plaque psoriasis and a significant capital raise.

Alumis Inc. reported its first-quarter 2026 financial results, highlighting progress in its clinical-stage biopharmaceutical development and a strong cash position.

Alumis Inc. reported a reduced net loss in Q3 2025, driven by a bargain purchase gain from the ACELYRIN merger, while significantly increasing R&D and administrative expenses to advance its clinical pipeline.

Alumis Inc. reported a net income of $59.3 million for Q2 2025, driven by a significant gain from the ACELYRIN Merger, while advancing its lead product candidates envu and A-005 in clinical trials.

Alumis Inc. reports a net loss for Q1 2025 and provides updates on its merger with ACELYRIN, clinical trials, and a collaboration agreement with Kaken Pharmaceutical.

Alumis Inc. reports a net loss of $93.1 million for the third quarter of 2024, alongside significant increases in research and development expenses following its recent IPO.

Alumis Inc. reports a net loss of $106.4 million for the six months ended June 30, 2024, while advancing its clinical programs and completing its IPO.

Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envu in plaque psoriasis, while also securing a $300 million at-the-market equity offering facility.

Alumis Inc. files an amendment to its 2024 Annual Report on Form 10-K to include Part III information and update certain disclosures.

Alumis Inc.'s 2024 10-K filing highlights the proposed merger with ACELYRIN, the clinical development of ESK-001 and A-005, and its financial position.

John R. Schroer, Chief Financial Officer of Alumis Inc., sold 3,282 shares of common stock on August 3, 2026 for $26.37 per share.

Sanam Pangali, Chief Legal Officer of Alumis Inc., sold 1,364 shares of common stock on August 3, 2026 for $26.37 per share.

Roy C. Hardiman, Chief Business & Strategy Ofcr of Alumis Inc., sold 2,692 shares of common stock on August 3, 2026 for $26.37 per share.

David M Goldstein, Chief Scientific Officer of Alumis Inc., sold 2,596 shares of common stock on August 3, 2026 for $26.37 per share.

Jorn Drappa, Chief Medical Officer of Alumis Inc., sold 2,447 shares of common stock on August 3, 2026 for $26.37 per share.

Mark Christopher Bradley, Chief Development Officer of Alumis Inc., sold 2,572 shares of common stock on August 3, 2026 for $26.37 per share.

Alumis Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 30, 2026, to elect directors and ratify auditor appointment.

Alumis Inc. has filed a definitive proxy statement for its 2025 Annual Meeting, outlining proposals for director elections and auditor ratification.

Alumis Inc. has announced its 2025 Annual Meeting of Stockholders, a virtual event set for July 30, 2025, to vote on the re-election of two Class I directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm.

Alumis Inc. is set to launch its IPO, aiming to raise $274 million to fuel the clinical development of its TYK2 inhibitors, ESK-001 and A-005, targeting immune-mediated diseases.

Alumis Inc., a clinical-stage biopharmaceutical company, has filed an amended S-1 registration statement for its initial public offering, planning to use the proceeds to advance its TYK2 inhibitor programs and other research initiatives.

Alumis Inc., a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an IPO, planning to use the proceeds to further develop its TYK2 inhibitor programs and other preclinical candidates.

Foresite Capital entities and James B. Tananbaum have collectively reported beneficial ownership of 14.5% of Latigo Biotherapeutics, Inc. common stock following the company's IPO.

Foresite Capital Fund VI LP and related entities have amended their Schedule 13D filing to reflect a disposition of Alumis Inc. common stock.

Samsara BioCapital and Opportunity Fund increased their beneficial ownership in Alumis Inc. to 5.4% through recent open market purchases and participation in a public offering.

Foresite Capital and its affiliates have updated their beneficial ownership in Alumis Inc. to 14.1% following recent share acquisitions and a follow-on offering.

Samsara BioCapital and its affiliates, including Dr. Srinivas Akkaraju, have increased their beneficial ownership in Alumis Inc. to 5.3% through recent open market purchases.

Samsara BioCapital and related entities have reduced their beneficial ownership in Alumis Inc. to below 5% through recent share sales and transfers.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 5.5% of Alumis Inc.'s common stock as of June 30, 2026.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, reporting beneficial ownership of 7,362,035 shares of Alumis Inc. common stock, representing 5.98% of the class.

venBio Global Strategic Fund IV, L.P. and its affiliates reported a 4.8% beneficial ownership stake in Alumis Inc., totaling 4,619,803 shares of common stock as of June 30, 2025.